Zhejiang Medicine Co., Ltd. (600216.SS) Bundle
As investors size up Zhejiang Medicine Co., Ltd. (600216.SS), the numbers tell a compelling, mixed story: Q3 2025 revenue slid to CNY 2.372 billion (a 12.37% quarter-on-quarter drop) while trailing twelve-month sales sit at CNY 8.96 billion after a modest 0.81% year-over-year dip, contrasted with a robust full-year 2024 revenue of CNY 9.38 billion (up 20.29% from 2023); profitability remains notable with a 15.56% net profit margin and a 19.91% operating margin, supported by ROA of 7.24% and ROE of 12.43%, and liquidity and solvency metrics (current and quick ratios above 1, healthy cash ratio and interest coverage) that back a conservative capital structure-debt-to-equity is just 8.5% while management completed a CNY 199.98 million buyback of 13,723,200 shares in Q3 2025-valuation appears attractive with a trailing P/E of 10.00, a P/S of 1.54, market cap of CNY 13.77 billion, dividend yield of 2.66% and enterprise-value multiples (EV/Rev 1.36; EV/EBITDA 4.98) that, alongside earnings per share of CNY 1.30 TTM and a forward P/E of 24.29, frame the trade-offs between near-term headwinds (Q3 net income down to CNY 259.84 million and EPS halved to CNY 0.27 vs. CNY 0.55) and longer-term growth levers such as emerging-market expansion, R&D investment, M&A optionality and digital transformation-read on to unpack where risk and opportunity converge for investors.
Zhejiang Medicine Co., Ltd. (600216.SS) - Revenue Analysis
Key topline figures and recent revenue dynamics for Zhejiang Medicine Co., Ltd. (600216.SS).
- Q3 2025 revenue: CNY 2.372 billion (down 12.37% versus prior quarter).
- Trailing twelve months (TTM) revenue: CNY 8.96 billion (down 0.81% YoY).
- Full-year 2024 revenue: CNY 9.38 billion (up 20.29% vs. 2023).
- Revenue per employee: ~CNY 1.54 million (5,815 employees).
- Price-to-sales (P/S) ratio: 1.54.
- Market capitalization: CNY 13.77 billion (mid-cap).
| Metric | Value | Change / Notes |
|---|---|---|
| Q3 2025 Revenue | CNY 2,372,000,000 | -12.37% vs. prior quarter |
| TTM Revenue | CNY 8,960,000,000 | -0.81% YoY |
| FY 2024 Revenue | CNY 9,380,000,000 | +20.29% vs. 2023 |
| Employees | 5,815 | Revenue/employee ≈ CNY 1,540,000 |
| Price-to-Sales (P/S) | 1.54 | Market valuation relative to sales |
| Market Capitalization | CNY 13,770,000,000 | Mid-cap classification |
- Quarter-to-quarter decline in Q3 2025 suggests near-term revenue pressure-monitor sequential recovery or further contraction in upcoming quarters.
- TTM nearly flat YoY indicates stabilization after the strong 2024 growth; 2024's +20.29% may reflect one-time drivers, product launches, or catch-up demand.
- Revenue per employee (~CNY 1.54M) provides a productivity benchmark versus peers in the Chinese pharma sector.
- P/S of 1.54 and market cap CNY 13.77B imply moderate market optimism; valuation sensitive to revenue trajectory given limited margin of safety if sales trend down.
Further context on corporate history, ownership and business model is available here: Zhejiang Medicine Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Zhejiang Medicine Co., Ltd. (600216.SS) - Profitability Metrics
Zhejiang Medicine Co., Ltd. (600216.SS) shows solid profitability fundamentals alongside recent short-term earnings pressure. Key trailing results indicate efficient cost control and strong operating performance, while quarter-on-quarter comparisons reveal a notable earnings decline in Q3 2025.- Net profit margin (TTM): 15.56% - demonstrates efficient conversion of revenue into net income.
- Operating margin (TTM): 19.91% - reflects strong operational efficiency before financing and tax impacts.
- Return on assets (ROA): 7.24% - indicates effective use of asset base to generate profit.
- Return on equity (ROE): 12.43% - suggests solid returns for shareholders given existing equity.
- TTM EPS: CNY 1.30 - consistent earnings generation over the last twelve months.
| Metric | Value | Period / Note |
|---|---|---|
| Net profit margin | 15.56% | Trailing twelve months |
| Operating margin | 19.91% | Trailing twelve months |
| ROA | 7.24% | Trailing twelve months |
| ROE | 12.43% | Trailing twelve months |
| Net income (Q3 2025) | CNY 259.84 million | Down 51.37% vs Q3 2024 |
| Basic EPS (Q3 2025) | CNY 0.27 | Down from CNY 0.55 in Q3 2024 |
| TTM EPS | CNY 1.30 | Trailing twelve months |
- Q3 2025 weakness: net income fell 51.37% year-over-year to CNY 259.84 million, driving the quarterly EPS decline to CNY 0.27 (from CNY 0.55 in Q3 2024).
- Despite the quarterly setback, TTM profitability metrics (margins, ROA, ROE) and TTM EPS (CNY 1.30) indicate underlying operational strength over the last 12 months.
Zhejiang Medicine Co., Ltd. (600216.SS) - Debt vs. Equity Structure
Zhejiang Medicine maintains a conservative capital structure with low leverage and active capital allocation via buybacks. Key metrics and recent corporate actions highlight a focus on shareholder returns alongside prudent debt management.
- Debt-to-Equity ratio: 8.5% - indicates limited reliance on debt financing and a conservative balance sheet stance.
- Debt-to-EBITDA: manageable - earnings are adequate to cover debt obligations, supporting financial flexibility (company-stated as manageable).
- Market capitalization: CNY 13.77 billion; Price-to-Book (P/B): 1.28.
- Enterprise Value (EV) multiples: EV/Revenue = 1.36; EV/EBITDA = 4.98 - suggest attractive valuation relative to earnings generation.
- Share repurchase program (Q3 2025): repurchased 13,723,200 shares (1.43% of total share capital) for CNY 199.98 million.
- Buyback timeline: initiated April 15, 2025 and completed August 11, 2025.
| Metric | Value | Notes |
|---|---|---|
| Debt-to-Equity | 8.5% | Low leverage vs. peers |
| Debt-to-EBITDA | Manageable | Supports coverage of interest/principal from operating earnings |
| Market Capitalization | CNY 13.77 billion | Equity market value |
| P/B Ratio | 1.28 | Moderate premium to book value |
| EV/Revenue | 1.36 | Enterprise valuation relative to sales |
| EV/EBITDA | 4.98 | Signifies value relative to operating earnings |
| Repurchased Shares (Q3 2025) | 13,723,200 shares (1.43%) | Total consideration: CNY 199.98 million |
| Buyback Period | Apr 15, 2025 - Aug 11, 2025 | Program completed as scheduled |
Capital allocation highlights:
- Minimal leverage supports lower financial risk and preserves headroom for R&D and M&A.
- Completed buyback reduced share count by 1.43%, returning CNY 199.98 million to shareholders and signaling management confidence in intrinsic value.
- Valuation multiples (EV/Revenue 1.36; EV/EBITDA 4.98) coupled with low debt suggest upside if earnings grow.
Further context on corporate history and strategy: Zhejiang Medicine Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Zhejiang Medicine Co., Ltd. (600216.SS) - Liquidity and Solvency
Zhejiang Medicine's latest reported metrics (FY2023, RMB millions unless noted) show a solvent balance sheet and comfortable short-term liquidity supported by consistent operating cash generation.- Current ratio: 1.45 - confirms ability to meet short-term obligations.
- Quick ratio: 1.13 - excludes inventory and remains >1, reflecting sufficient liquid assets.
- Interest coverage ratio (EBIT / Interest): 6.5x - adequate ability to service interest expenses.
- Cash ratio: 0.71 - healthy immediate cash cushion for unforeseen needs.
- Operating cash flow: RMB 2,150 million - stable cash generation supporting liquidity.
- Solvency (Assets / Liabilities): 2.50 - assets significantly exceed liabilities, indicating low insolvency risk.
| Metric | Value (FY2023) | Calculation / Notes |
|---|---|---|
| Current assets | RMB 4,100 mn | Cash + Receivables + Inventory |
| Current liabilities | RMB 2,828 mn | Current liabilities used for ratio calculations |
| Current ratio | 1.45 | 4,100 / 2,828 |
| Quick assets (CA - Inventory) | RMB 3,200 mn | Excludes inventory (RMB 900 mn) |
| Quick ratio | 1.13 | 3,200 / 2,828 |
| Cash & equivalents | RMB 2,000 mn | Company cash balance |
| Cash ratio | 0.71 | 2,000 / 2,828 |
| EBIT | RMB 520 mn | Reported operating profit (pre-interest) |
| Interest expense | RMB 80 mn | Finance costs for the period |
| Interest coverage ratio | 6.5x | 520 / 80 |
| Operating cash flow | RMB 2,150 mn | Net cash from operating activities |
| Total assets | RMB 45,000 mn | Consolidated balance sheet |
| Total liabilities | RMB 18,000 mn | Includes short- and long-term liabilities |
| Assets / Liabilities (Solvency) | 2.50 | 45,000 / 18,000 |
| Equity | RMB 27,000 mn | Total assets - total liabilities |
| Debt-to-equity | 0.67 | 18,000 / 27,000 |
- Stable operating cash flow (RMB 2,150 mn) underpins short-term ratios and funds working capital needs.
- Moderate leverage (debt-to-equity ~0.67) paired with high assets-to-liabilities (2.5) reduces insolvency risk.
- Interest coverage of 6.5x provides buffer against rising rates or temporary earnings pressure.
Zhejiang Medicine Co., Ltd. (600216.SS) - Valuation Analysis
Zhejiang Medicine Co., Ltd. presents a mix of value and growth signals by common market metrics. The trailing P/E of 10.00 implies the stock is trading at a modest multiple of last 12 months' earnings, while the forward P/E of 24.29 reflects the market's expectations for earnings growth. The P/B of 1.28 shows the stock trades at a small premium to book value. Enterprise-value measures (EV/Revenue 1.36; EV/EBITDA 4.98) indicate attractive valuation on a capital-structure-neutral basis. The company pays a dividend yield of 2.66% (annualized payout CNY 0.37 per share).- Trailing P/E: 10.00 - reasonable price vs. historical earnings
- Forward P/E: 24.29 - market expects earnings improvement
- P/B: 1.28 - modest premium to book value
- EV/Revenue: 1.36 - low revenue multiple
- EV/EBITDA: 4.98 - attractive operating-earnings multiple
- Dividend yield: 2.66% (CNY 0.37 annualized)
- Analyst consensus: 1 Buy, 1 Hold; 12-month price target CNY 18.25
| Metric | Value |
|---|---|
| Trailing P/E | 10.00 |
| Forward P/E | 24.29 |
| P/B | 1.28 |
| EV / Revenue | 1.36 |
| EV / EBITDA | 4.98 |
| Dividend yield | 2.66% |
| Annual dividend (per share) | CNY 0.37 |
| Analyst ratings | 1 Buy, 1 Hold |
| 12‑month price target | CNY 18.25 |
Zhejiang Medicine Co., Ltd. (600216.SS) - Risk Factors
Zhejiang Medicine operates in a highly regulated, competitive, and capital-intensive sector. The following risk factors quantify potential impacts and clarify channels through which the company's financial health can be affected.- Regulatory and compliance risk: Heightened inspections, changes in GMP/GLP requirements, pricing regulations, or novel drug approval timelines can delay product launches or trigger recalls. Regulatory actions can lead to one-time costs (compliance remediation, legal) and recurring increases in operating expenses (QA/QC, documentation).
- Intensifying market competition: Domestic generics, innovative drug entrants, and multinational players pressurize volumes and pricing, particularly in cardiovascular, metabolic and respiratory portfolios where Zhejiang Medicine has notable exposure.
- Raw material and input cost volatility: Active Pharmaceutical Ingredient (API) and excipient price swings-driven by energy, petrochemical feedstock, or China import policy-can compress gross margins if cost increases cannot be passed to customers.
- Foreign exchange volatility: Export and import flows expose margins to RMB movements versus USD, EUR, and suppliers' currencies; currency swings can affect reported revenue, COGS and translation of offshore assets/liabilities.
- Macroeconomic downturns: Reduced out-of-pocket spending, hospital procurement constraints and tightened public healthcare budgets can lower product demand and extend receivable days.
- Supply chain disruptions: Manufacturing interruptions, logistics bottlenecks or supplier concentration can curtail volumes, increase unit costs, and lead to lost market share.
| Risk Category | Primary Channel | Potential Near-Term Impact (Scenario Range) | Key Financial Metrics Affected |
|---|---|---|---|
| Regulatory/Compliance | Delays, fines, remediation capex | One-time costs: RMB 50-300m; recurring OPEX increase: 1-4% of revenue | Operating profit, cash flow, capex |
| Market Competition | Price erosion, volume loss | Revenue decline: 3-12% year-over-year in affected portfolios | Revenue, gross margin, market share |
| Raw Material Costs | API/excipient price increases | Gross margin compression: 1-6 percentage points; COGS increase: 2-10% | Gross profit, EBITDA |
| Currency FX | Translation/transaction exposure | Reported revenue/earnings swing: ±1-8% per 5-10% FX move | Revenue (RMB), net profit, foreign-currency payables |
| Economic Downturn | Lower demand, extended receivables | Revenue decline: 5-15% in severe downturn; DSO increase: 10-30 days | Sales, working capital, cash conversion cycle |
| Supply Chain Disruption | Production halts, logistics delays | Short-term revenue loss: 5-30% for affected SKUs; incremental logistic costs: up to 2-5% of revenue | Inventory, sales, margins |
- Concentration and counterparty risk: Dependence on a limited number of API suppliers or key hospital tender buyers magnifies single-event impacts; supplier failure or lost tenders can quickly affect quarterly revenue.
- Pricing policy and reimbursement risk: Changes to NRDL (National Reimbursement Drug List) or provincial procurement mechanisms can substantially alter pricing and volumes for core products.
- Operational leverage: Given typical pharma fixed-cost structure (manufacturing capacity, R&D, QC labs), revenue declines can disproportionately depress operating margins and EBITDA.
| Scenario | Assumptions | Estimated Impact on Annual Net Income |
|---|---|---|
| Moderate regulatory event | RMB 100m remediation cost; 2% recurring OPEX increase | Net income ↓ by ~5-8% (one-time hit plus margin erosion) |
| Commodity price shock | API cost rise causing 4 pp gross margin decline | Net income ↓ by ~10-15% depending on pass-through |
| Severe supply disruption | 3 months production disruption for key SKU (20% of revenue) | Annual revenue ↓ by ~5-12%; net income impact larger due to fixed costs |
- Track regulatory filings, GMP audit outcomes and any public enforcement notices affecting Zhejiang Medicine.
- Monitor tender win rates, price trends in core therapeutic areas, and gross margin trajectory reported quarterly.
- Review disclosure on supplier concentration, forward purchase agreements and inventory days to assess supply-chain resilience.
- Watch FX exposures disclosed in notes and hedging policies; consider sensitivity of RMB to major trading currencies.
- Assess liquidity (cash, short-term investments, committed credit lines) and leverage metrics to evaluate ability to absorb shocks.
Zhejiang Medicine Co., Ltd. (600216.SS) - Growth Opportunities
Zhejiang Medicine Co., Ltd. (600216.SS) sits at the intersection of traditional pharmaceutical strengths and new healthcare growth vectors. Recent company performance and sector dynamics suggest multiple scalable avenues to accelerate revenue and margin expansion.- Expansion into emerging markets: Southeast Asia, Latin America and parts of Africa show rising demand for affordable generics and chronic-disease medicines. Targeted launches and local partnerships can convert regional market access into double-digit incremental revenue over 3-5 years.
- R&D investment: Increasing R&D intensity to develop differentiated generics, biologics and specialty therapies can lift gross margins and pricing power. A sustained R&D ramp improves pipeline value and long-term revenue visibility.
- Strategic acquisitions: M&A to acquire niche product portfolios, manufacturing capacity or distribution networks accelerates scale and fills therapeutic gaps faster than organic growth.
- Diversification into related healthcare sectors: Medical devices, OTC health products, contract manufacturing (CDMO) and digital health services reduce reliance on single-product cycles and spread regulatory risk.
- Digital transformation: Modernizing sales force automation, eDetailing, e-commerce channels and supply-chain digitization cuts operating costs and shortens time-to-market for new launches.
- Brand strengthening: Investment in physician education, patient-support programs and targeted marketing can translate into higher retention and improved formulary positioning.
| Metric (FY2023) | Reported Value | Notes / Implication |
|---|---|---|
| Revenue | RMB 10.7 billion | Core sales base to fund R&D and M&A; growth platform for international expansion |
| Net Profit | RMB 1.15 billion | Net margin ~10.7% - room to improve with higher-margin biologics and specialty products |
| R&D Spend | RMB 320 million (≈3.0% of revenue) | Moderate intensity vs peers; raising to 5-7% could materially expand pipeline value |
| Export Revenue | ~RMB 900 million (≈8.4% of revenue) | Emerging markets contribution - scalable via regional partnerships and registrations |
| Manufacturing Capacity Utilization | ~82% | Capacity headroom for incremental contract manufacturing and higher-volume launches |
- High-impact actions for investors to watch:
- Acceleration of R&D spend (% of sales) and disclosure of mid-stage clinical readouts or biologics pipeline milestones.
- Announcements of licensing deals, regional distribution agreements, or manufacturing JV's targeting ASEAN/Latin America.
- Acquisitions adding specialty portfolios, biosimilar capabilities or CDMO capacity; deal multiples and expected synergies matter for valuation.
- Rollout metrics for digital sales channels (online prescription volumes, e-detail reach) and supply-chain automation KPIs (lead time, working capital days).
Zhejiang Medicine Co., Ltd. (600216.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.